六氟-1,25-二羟基维生素D3治疗斑块状银屑病的使用原理及临床反应：一项初步研究。

Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study.

作者信息

Durakovic C, Malabanan A, Holick M F

机构信息

Vitamin D, Skin, and Bone Research Laboratory, Section of Endocrinology, Nutrition and Diabetes, Department of Medicine, Boston University School of Medicine, 715 Albany St, M-1013, Boston, MA 02118, USA.

出版信息

Br J Dermatol. 2001 Mar;144(3):500-6. doi: 10.1046/j.1365-2133.2001.04075.x.

DOI:10.1046/j.1365-2133.2001.04075.x

PMID:11260006

Abstract

BACKGROUND

Vitamin D analogues are useful in topical therapy of psoriasis.

OBJECTIVES

To evaluate the effect of hexafluoro-1,25-dihydroxyvitamin D3 (F6-1,25(OH)2D3) in treatment of psoriasis.

METHODS

Fifteen patients with plaque-type psoriasis were enrolled in a single centre double-blind, right/left comparison, placebo-controlled study, and received 0.1 g of petrolatum containing 5 microg of F6-1,25(OH)2D3 or 0.1 g of petrolatum (placebo) for 3 months. After completion of this double-blind study, a subset of these patients (n = 12) applied F6-1,25(OH)2D3 ointment (50 microg g-1 of petrolatum) to all their lesions (total area, 100-5000 cm2, mean area: 3300 m2) for 2 months as a single application at night.

RESULTS

The mean severity score in the right/left-sided controlled topical F6-1,25(OH)2D3 (50 microg g-1) therapy group showed a decrease of 85%. In contrast, the mean severity score for the placebo-treated areas showed a decrease of 45% (P < 0.001). In the 12 patients who subsequently applied F6-1,25(OH)2D3 (50 microg g-1) ointment to all of their lesions, 91.6% showed moderate to excellent improvement. The mean Psoriasis Area and Severity Index score decreased by 44.9% (from 33.6 +/- 15 to 18.5 +/- 13). No effect on calcium homeostasis was noted. Adverse events included mild irritation in two patients that resolved during therapy.

CONCLUSIONS

Topical F6-1,25(OH)2D3 is a safe and effective once a day treatment for psoriasis.

摘要

背景

维生素D类似物在银屑病的局部治疗中有用。

目的

评估六氟-1,25-二羟基维生素D3（F6-1,25(OH)2D3）治疗银屑病的效果。

方法

15例斑块型银屑病患者参加了一项单中心双盲、左右对照、安慰剂对照研究，接受含5μg F6-1,25(OH)2D3的凡士林0.1g或凡士林（安慰剂）治疗3个月。在这项双盲研究完成后，这些患者中的一部分（n = 12）将F6-1,25(OH)2D3软膏（50μg/g凡士林）一次性在夜间涂抹于所有皮损处（总面积100 - 5000cm²，平均面积：3300m²），持续2个月。

结果

右侧/左侧对照的局部F6-1,25(OH)2D3（50μg/g）治疗组的平均严重程度评分下降了85%。相比之下，安慰剂治疗区域的平均严重程度评分下降了45%（P < 0.001）。在随后将F6-1,25(OH)2D3（50μg/g）软膏涂抹于所有皮损的12例患者中，91.6%显示中度至显著改善。银屑病面积和严重程度指数平均评分下降了44.9%（从33.6±15降至18.5±13）。未观察到对钙稳态的影响。不良事件包括2例患者出现轻度刺激，在治疗期间缓解。